Standard BioTools Announces Third Quarter 2022 Financial Results
08 nov. 2022 16h05 HE
|
Standard BioTools Inc.
Third quarter core product and services revenue increase of 30% sequentially to $24.8 million First phase of restructuring program improves operating margin by 600 to 800 basis points, or $8.0...
Standard BioTools and Visiopharm Announce Partnership for the Development of Complete Image Analysis Solutions to be Packaged With Hyperion and Hyperion+ Imaging Systems
07 nov. 2022 16h05 HE
|
Standard BioTools Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – and...
Standard BioTools Announces Conference Call and Webcast of Third Quarter 2022 Financial Results
25 oct. 2022 08h30 HE
|
Standard BioTools Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today...
Ascendas Genomics Receives NMPA Approval for Use of Standard BioTools Microfluidics Technology to Advance the Development of Molecular Diagnostics in China
13 oct. 2022 08h30 HE
|
Standard BioTools Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today...
Standard BioTools Releases the X9 Real-Time PCR System, Its Most Productive and Flexible High-Capacity Genomics Platform
06 oct. 2022 08h30 HE
|
Standard BioTools Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today...
Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
25 août 2022 16h05 HE
|
Standard BioTools Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that the Compensation Committee of its Board of Directors, which is composed...
Standard BioTools Announces Second Quarter 2022 Financial Results and Provides Strategic Update
08 août 2022 16h02 HE
|
Standard BioTools Inc.
Second quarter revenue of $18.8 million Completed $250 million strategic cash infusion from Casdin Capital and Viking Global Upgraded management team and added board members to bring significant...
Standard BioTools Announces Conference Call and Webcast of Second Quarter 2022 Financial Results
25 juil. 2022 16h30 HE
|
Standard BioTools Inc.
SOUTH SAN FRANCISCO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today...
Standard BioTools Announces First Quarter 2022 Financial Results
05 mai 2022 16h02 HE
|
Standard BioTools Inc.
SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today...
Standard BioTools Announces Conference Call and Webcast of First Quarter 2022 Financial Results
22 avr. 2022 16h02 HE
|
Standard BioTools Inc.
SOUTH SAN FRANCISCO, Calif., April 22, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today...